Furthermore, in pre-clinical xenograft immunodeficient mouse models, anti-CD47 mAbs are used at high doses to induce tumor suppression, potentially over-estimating the likely efficacy of CD47 blockade in humans even in combination with direct targeting mAbs. Here, CD47 is linked to neoplasm.